We are monitoring the path of Hurricane Milton.

Pediatric Oncology Clinical Trials

All Studies
AALL1521 INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
AALL1631 International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
AALL1731 temp close 12/19/2022 A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome BLymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl
AALL1732
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk BALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
 Lymphoma
ANHL1931
A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
All Relapse
AALL1621
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
AALL1821 Groups 1, 2 & 3 Temporary Closure
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse 
APAL2020SC
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
AML
AAML1831
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
AAML18P1
Stopping Tyrosine Kinase Inhibitors (TKI) to AssessTreatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Neuroblastoma
ANBL00B1
Children's Oncology Group Neuroblastoma Biology Studies
ANBL1531
A Phase 3 Study of 131I-Metaiodobenzlguanidine (131I-MIBG) or Crizotinib Added To Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
ANBL1232 Group B open Groups A2 and C Temporary Closure
Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study.
ANBL1821 Temporary closure
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
ANBL19P1 Temporary closure 06/27/2022
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
CNS
ACNS1422
A Phase 2 Study of Reduced Therapy for Newly Diagnosed AverageRisk WNT-Driven Medulloblastoma Patients
ACNS1723
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
ACNS1831
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma
ACNS1833
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
ACNS1931 Stratum 1 Closed
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination with Vinblastine for Non-NF1, Non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
ACNS2031
A Phase 3 Study of Sodium Thiosulfate for Reduction of CisplatinInduced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features
Renal / Germ Cell
AREN03B2
Renal Tumors Classification, Biology, and Banking Study
AGCT1531 AVA Hears Temporary Closure 0212/2021
A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532
Phase 3 Accelerated BEP Trial: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors
AREN1921  Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Osteosarcoma
AOST2031
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Liver
AHEP1531 Temporary Closure of Accrual to Group D, effective June 30, 2023
AHEP1531 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Hodgkin's
AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
S1826 temp closure 10/5/2022
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Soft Tissue Sarcoma
ARST2031
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINOCPO Maintenance
ARST2032
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Solid Tumor Relapse
APEC1621-Master APEC1621-Master NCI-COG Pediatric Match (Molecular Analysis For Therapy Choice) Master VersionControl Protocol
Hematology Protocols
CSEG101B2201
A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with VasoOcclusive Crisis
Other Studies
ACCL20N1CD
Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
ACCL21C2
Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
ALTE07C1
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer: A Groupwide Non-Therapeutic Study
DCP-001
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Research Program (NCORP)
ALTE2031
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
APEC14B1
The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study